Forecasting cardiovascular risk reduction with semaglutide in overweight and obese with heart disease: a nationwide cohort study.

COI Statement

Conflict of interest: K.G.S.: advisory board: Sanofi; T.B.-S. is a chief investigator of the Boston Scientific financed ‘DANLOGIC-HF’ trial; chief investigator of the Sanofi Pasteur financed ‘NUDGE-FLU’ trial; chief investigator of the Sanofi Pasteur financed ‘DANFLU-1’ trial; chief investigator of the Sanofi Pasteur financed ‘DANFLU-2’ trial; steering committee member of the Boston Scientific sponsored ‘LUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific’s Investigational ICM System’ trial; steering committee member of the Amgen sponsored GALACTIC-HF trial; and steering committee member of the Boehringer Ingelheim financed EASi-KIDNEY trial; advisory board: Sanofi Pasteur, Amgen, CSL Seqirus, and GSK; speaker honorarium: Bayer, Novartis, Sanofi Pasteur, GE HealthCare, and GSK; research grants: Boston Scientific, GE HealthCare, AstraZeneca, Novo Nordisk, and Sanofi Pasteur; and consultant appointments: Novo Nordisk, IQVIA, and Parexel. M.V. has received research grant support, served on advisory boards, or had speaker engagements with American Regent, Amgen, AstraZeneca, Bayer AG, Baxter Healthcare, BMS, Boehringer Ingelheim, Chiesi, Cytokinetics, Lexicon Pharmaceuticals, Merck, Novartis, Novo Nordisk, Pharmacosmos, Relypsa, Roche Diagnostics, Sanofi, and Tricog Health, and participates on clinical trial committees for studies sponsored by AstraZeneca, Galmed, Novartis, Bayer AG, Occlutech, and Impulse Dynamics. All other authors have nothing to disclose.